Industry › BioTech
Press Releases
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Eisai
Dec 05, 2024 10:22 HKT/SGT
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Everest Medicines Limited
Dec 04, 2024 11:08 HKT/SGT
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Everest Medicines Limited
Dec 04, 2024 10:59 HKT/SGT
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Everest Medicines Limited
Dec 04, 2024 10:48 HKT/SGT
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Everest Medicines Limited
Dec 02, 2024 10:34 HKT/SGT
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Hua Medicine
Nov 30, 2024 21:08 HKT/SGT
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Hua Medicine
Nov 30, 2024 20:34 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Eisai
Nov 28, 2024 15:26 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai
Nov 15, 2024 13:31 HKT/SGT
